Asia-Pacific Anti-Inflammatory Therapeutics Market

CHAPTER 1 INTRODUCTION

1.1 Report Description
1.2 Key Market Benefits
1.3 Key Market Segments
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO perspective

CHAPTER 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Key findings

3.2.1 Top impacting factors
3.2.2 Top investment pockets
3.2.3 Top winning strategies

3.3 Government Regulations
3.4 Reimbursement Scenario
3.5 Porters Five Force Analysis

3.5.1 Complex and highly differentiated nature of raw materials increases bargaining power of suppliers
3.5.2 Fewer manufacturers of anti-inflammatory drugs limits the bargaining power of buyers
3.5.3 High capital investment and patent provision lowers the threats from new entrants
3.5.4 Difficulty to imitate the original biologics lowers the threat of substitutes
3.5.5 Industry rivalry is low to moderate due to presence of few competitors

3.6 Value chain analysis
3.7 Clinical Trials
3.8 Patent Analysis
3.9 Market Share Analysis, (2014)
3.10 Market dynamics

3.10.1 Drivers

3.10.1.1 Rising incidences of autoimmune and respiratory conditions:
3.10.1.2 New Drugs in Pipeline
3.10.1.3 Increasing adoption rate of anti-inflammatory drugs

3.10.2 Restraints

3.10.2.1 Side Effects of Anti-Inflammatory Drugs
3.10.2.2 Patent expirations

3.10.3 Opportunities

3.10.3.1 Developing biosimilars for the existing drugs
3.10.3.2 Tapping the emerging markets in developing regions

CHAPTER 4 BY INDICATION

4.1 Arthritis

4.1.1 Market size and forecast
4.1.2 Rheumatoid Arthritis
4.1.3 Osteoarthritis
4.1.4 Ankylosing Spondylitis
4.1.5 Psoriatic Arthritis
4.1.6 Gout

4.2 Respiratory Diseases

4.2.1 Market size and forecast
4.2.2 Asthma
4.2.3 Chronic obstructive pulmonary disease (COPD)

4.3 Multiple Sclerosis

4.3.1 Market size and forecast by region

4.4 Psoriasis

4.4.1 Market size and forecast

4.5 Inflammatory Bowel Disease (IBD)

4.5.1 Market size and forecast
4.5.2 Crohns Disease
4.5.3 Ulcerative Colitis

4.6 Other Inflammatory Diseases

4.6.1 Market size and forecast

CHAPTER 5 BY DRUG CLASS

5.1 Anti-inflammatory Biologics

5.1.1 Key Market Trends
5.1.2 Market Growth factors and opportunities
5.1.3 Market size and forecast

5.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

5.2.1 Key Market Trends
5.2.2 Market growth factors and opportunities
5.2.3 Market size and forecast

5.3 Corticosteroids

5.3.1 Key Market Trends
5.3.2 Market Growth factors and opportunities
5.3.3 Market size and forecast
5.4 Other anti-inflammatory drugs

CHAPTER 6 BY COUNTRY

6.1 Key market trends
6.2 Key growth factors and opportunities

6.2.1 Market size and forecast

6.3 Japan

6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast

6.4 China

6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast

6.5 India

6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast

6.6 Australia

6.6.1 Key market trends
6.6.2 Key growth factors and opportunities
6.6.3 Market size and forecast

6.7 South Korea

6.7.1 Key market trends
6.7.2 Key growth factors and opportunities
6.7.3 Market size and forecast

6.8 Indonesia

6.8.1 Key market trends
6.8.2 Key growth factors and opportunities
6.8.3 Market size and forecast

6.9 Rest of Asia Pacific

CHAPTER 7 COMPANY PROFILES

7.1 Pfizer Inc.

7.1.1 Company overview
7.1.2 Company snapshot
7.1.3 Business performance
7.1.4 Strategic moves and developments
7.1.5 SWOT analysis & strategic conclusions

7.2 AbbVie Inc.

7.2.1 Company overview
7.2.2 Company snapshot
7.2.3 Business performance
7.2.4 Strategic Moves and Developments
7.2.5 SWOT analysis & strategic conclusions

7.3 Johnson & Johnson

7.3.1 Company overview
7.3.2 Company snapshot
7.3.3 Business performance
7.3.4 Strategic Moves and Developments
7.3.5 SWOT analysis & strategic conclusions

7.4 GlaxoSmithKline plc

7.4.1 Company Overview
7.4.2 Company snapshot
7.4.3 Business performance:
7.4.4 Strategic moves and developments
7.4.5 SWOT analysis & strategic conclusions

7.5 Merck & Co., Inc.

7.5.1 Company overview
7.5.2 Company snapshot
7.5.3 Business Performance
7.5.4 Strategic Moves and Developments
7.5.5 SWOT analysis and strategic conclusions

7.6 Novartis AG

7.6.1 Company overview
7.6.2 Company snapshot
7.6.3 Business Performance
7.6.4 Strategic moves and developments
7.6.5 SWOT analysis and strategic conclusions

7.7 F. Hoffmann-La Roche AG

7.7.1 Company profile
7.7.2 Company snapshot
7.7.3 Business Performance
7.7.4 Strategic moves and developments
7.7.5 SWOT analysis and strategic conclusions

7.8 Eli Lily and Company

7.8.1 Company overview
7.8.2 Company snapshot
7.8.3 Business performance
7.8.4 Strategic Moves and Developments
7.8.5 SWOT analysis and strategic conclusions

7.9 AstraZeneca PLC.

7.9.1 Company overview
7.9.2 Company snapshot
7.9.3 Business performance
7.9.4 Strategic Moves and Developments
7.9.5 SWOT analysis and strategic conclusions

7.10 Amgen Inc.

7.10.1 Company overview
7.10.2 Company snapshot
7.10.3 Business performance
7.10.4 Strategic Moves and Developments
7.10.5 SWOT analysis and strategic conclusions

List of Figures

FIG. 1 TYPES OF ANTI-INFALMMATORY THERAPEUTICS
FIG. 2 TOP FACTORS IMPACTING ON ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET (2014-2020)
FIG. 3 TOP INVESTMENT POCKETS OF ANTI-INFLAMMATORY THERAPEUTICS MARKET (2014)
FIG. 4 TOP WINNING STRATEGIES IN ANTI-INFLAMMATORY THERAPEUTICS MARKET (2012-2015)
FIG. 5 PORTERS FIVE FORCES ANALYSIS
FIG. 6 VALUE CHAIN OF ANTI-INFLAMMATORY THERAPEUTICS MARKET
FIG. 7 MARKET SHARE ANALYSIS, (2014)
FIG. 8 PFIZER FINANCIAL REVENUES BY BUSINESS SEGMENTS (2014)
FIG. 9 PFIZER FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 10 PFIZER FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 11 PFIZER SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 12 ABBVIE, INC. FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 13 HUMIRA FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 14 ABBVIE SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 15 JOHNSON & JOHNSON PHARMACEUTICALS SALES BY GEOGRAPHY (2014)
FIG. 16 JOHNSON & JOHNSON SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 17 GLAXOSMITHKLINES FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 18 GLAXOSMITHKLINE FINANCIAL REVENUES BY THERAPY AREA
FIG. 19 GLAXOSMITHKLINE SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 20 MERCK FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 21 MERCK FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 22 MERCK SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 23 NOVARTIS FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 24 NOVARTIS FINANCIAL REVENUES BY SEGMENT (2014)
FIG. 25 NOVARTIS SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 26 ROCHE FIANANCIAL REVENUES BY THERAPEUTIC SEGMENTS (2014)
FIG. 27 ROCHE FINANCIAL REVENUES OF PHARMACEUTICALS BY REGION
FIG. 28 ROCHE SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 29 ELI LILLY FINANCIAL REVENUES BY BUSINESS SEGMENTS (2014)
FIG. 30 ELI LILLY SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
FIG. 31 ASTRAZENECA FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 32 ASTRAZENECA FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 33 ASTRAZENECA SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
FIG. 34 AMGEN FINANCIAL REVENUES BY PRODUCT (2014)
FIG. 35 AMGEN FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 36 AMGEN SWOT ANALYSIS AND STRATEGIC CONCLUSIONS

List of Tables

TABLE 1 CLINICAL TRIALS FOR ANTI-INFLAMMATORY DRUGS
TABLE 2 PATENT EXPIRY OF MAJOR BRANDS
TABLE 3 ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY INDICATION, 2014-2020, ($MILLION)
TABLE 4 ASIA-PACIFIC ARTHRITIS ANTI INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 5 ASIA-PACIFIC RESPIRATORY DISEASES ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 6 ASIA-PACIFIC MULTIPLE SCLEROSIS ANTI INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 7 ASIA-PACIFIC PSORIASIS ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 8 ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 9 ASIA-PACIFIC OTHER INFLAMMATORY DISEASES ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 10 ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 11 GLOBAL TOP SELLING BIOLOGIC ANTI-INFLAMMATORY BRANDS, 2014 ($MILLION)
TABLE 12 ASIA-PACIFIC ANTI-INFLAMMATORY BIOLOGICS THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 13 ASIA-PACIFIC NSAIDS ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 14 GLOBAL TOP SELLING CORTICOSTEROIDS ANTI-INFLAMMATORY BRANDS, 2014 ($MILLION)
TABLE 15 ASIA-PACIFIC CORTICOSTEROIDS ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 16 ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 17 JAPAN ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 18 CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 19 INDIA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 20 AUSTRALIA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 21 SOUTH KOREA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 22 INDONESIA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 23 REST OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 24 PFIZER INC SNAPSHOT
TABLE 25 ABBVIE INC. SNAPSHOT
TABLE 26 JOHNSON & JOHNSON SNAPSHOT
TABLE 27 GLAXOSMITHKLINE SNAPSHOT
TABLE 28 MERCK & CO SNAPSHOT
TABLE 29 NOVARTIS AG SNAPSHOT
TABLE 30 F. HOFFMANN-LA ROCHE AG SNAPSHOT
TABLE 31 ELI LILLY SNAPSHOT
TABLE 32 ASTRAZENECA SNAPSHOT
TABLE 33 AMGEN INC SNAPSHOT